Safety, Tolerability and Immunogenicity of Recombinant COVID-19 Vaccine Betuvax-CoV-2
Status:
Active, not recruiting
Trial end date:
2022-07-24
Target enrollment:
Participant gender:
Summary
Randomized, double-blind, multicenter parallel-group clinical study of safety, tolerability
and immunogenicity of the Betuvax-CoV-2 vaccine. The aim of this study is to investigate the
safety, tolerability and immunogenicity of the Betuvax-CoV-2 Recombinant vaccine for the
prevention of coronavirus infection caused by the SARS-CoV-2 virus, suspension for
intramuscular administration, 10 μg/ml and 40 μg/ml (Ltd. Institute of New Medical
Technologies, Russia) in healthy adult volunteers, aged 18 to 60 (inclusive).